Intranet
Acces
Contact
Accès direct
Unités de recherche
Bienvenue
M3i
Modèles Insectes d’Immunité Innée
Publications
2017
Saliba Hanadi, Heurtault Béatrice, Bouharoun-Tayoun Hasnaa, Flacher Vincent, Frisch Benoît, Fournel Sylvie, Chamat Soulaima
Enhancing tumor specific immune responses by transcutaneous vaccination Article de journal
Dans: Expert Review of Vaccines, vol. 16, no. 11, p. 1079–1094, 2017, ISSN: 1744-8395.
Résumé | Liens | BibTeX | Étiquettes: Administration, Cancer vaccine, Cancer Vaccines, Clinical Trials as Topic, Cutaneous, Dendritic Cells, Humans, liposome, Liposomes, nanoparticle, Nanoparticles, Neoplasms, Skin, skin dendritic cell, Team-Mueller, transcutaneous vaccination, Treatment Outcome, Vaccination
@article{saliba_enhancing_2017,
title = {Enhancing tumor specific immune responses by transcutaneous vaccination},
author = {Hanadi Saliba and Béatrice Heurtault and Hasnaa Bouharoun-Tayoun and Vincent Flacher and Benoît Frisch and Sylvie Fournel and Soulaima Chamat},
doi = {10.1080/14760584.2017.1382357},
issn = {1744-8395},
year = {2017},
date = {2017-01-01},
journal = {Expert Review of Vaccines},
volume = {16},
number = {11},
pages = {1079--1094},
abstract = {INTRODUCTION: Our understanding of the involvement of the immune system in cancer control has increased over recent years. However, the development of cancer vaccines intended to reverse tumor-induced immune tolerance remains slow as most current vaccine candidates exhibit limited clinical efficacy. The skin is particularly rich with multiple subsets of dendritic cells (DCs) that are involved to varying degrees in the induction of robust immune responses. Transcutaneous administration of cancer vaccines may therefore harness the immune potential of these DCs, however, this approach is hampered by the impermeability of the stratum corneum. Innovative vaccine formulations including various nanoparticles, such as liposomes, are therefore needed to properly deliver cancer vaccine components to skin DCs. Areas covered: The recent insights into skin DC subsets and their functional specialization, the potential of nanoparticle-based vaccines in transcutaneous cancer vaccination and, finally, the most relevant clinical trial advances in liposomal and in cutaneous cancer vaccines will be discussed. Expert commentary: To define the optimal conditions for mounting protective skin DC-induced anti-tumor immune responses, investigation of the cellular and molecular interplay that controls tumor progression should be pursued in parallel with clinical development. The resulting knowledge will then be translated into improved cancer vaccines that better target the most appropriate immune players.},
keywords = {Administration, Cancer vaccine, Cancer Vaccines, Clinical Trials as Topic, Cutaneous, Dendritic Cells, Humans, liposome, Liposomes, nanoparticle, Nanoparticles, Neoplasms, Skin, skin dendritic cell, Team-Mueller, transcutaneous vaccination, Treatment Outcome, Vaccination},
pubstate = {published},
tppubtype = {article}
}
INTRODUCTION: Our understanding of the involvement of the immune system in cancer control has increased over recent years. However, the development of cancer vaccines intended to reverse tumor-induced immune tolerance remains slow as most current vaccine candidates exhibit limited clinical efficacy. The skin is particularly rich with multiple subsets of dendritic cells (DCs) that are involved to varying degrees in the induction of robust immune responses. Transcutaneous administration of cancer vaccines may therefore harness the immune potential of these DCs, however, this approach is hampered by the impermeability of the stratum corneum. Innovative vaccine formulations including various nanoparticles, such as liposomes, are therefore needed to properly deliver cancer vaccine components to skin DCs. Areas covered: The recent insights into skin DC subsets and their functional specialization, the potential of nanoparticle-based vaccines in transcutaneous cancer vaccination and, finally, the most relevant clinical trial advances in liposomal and in cutaneous cancer vaccines will be discussed. Expert commentary: To define the optimal conditions for mounting protective skin DC-induced anti-tumor immune responses, investigation of the cellular and molecular interplay that controls tumor progression should be pursued in parallel with clinical development. The resulting knowledge will then be translated into improved cancer vaccines that better target the most appropriate immune players.
2008
Lacerda Lara, Herrero Maria A, Venner Kerrie, Bianco Alberto, Prato Maurizio, Kostarelos Kostas
Carbon-nanotube shape and individualization critical for renal excretion Article de journal
Dans: Small (Weinheim an Der Bergstrasse, Germany), vol. 4, no. 8, p. 1130–1132, 2008, ISSN: 1613-6829.
Liens | BibTeX | Étiquettes: Animals, Biological Transport, carbon, Electron, Female, Glomerular Filtration Rate, I2CT, Inbred BALB C, Kidney Glomerulus, Mice, Microscopy, Nanoparticles, nanotechnology, Nanotubes, Team-Bianco, Transmission
@article{lacerda_carbon-nanotube_2008,
title = {Carbon-nanotube shape and individualization critical for renal excretion},
author = {Lara Lacerda and Maria A Herrero and Kerrie Venner and Alberto Bianco and Maurizio Prato and Kostas Kostarelos},
doi = {10.1002/smll.200800323},
issn = {1613-6829},
year = {2008},
date = {2008-08-01},
journal = {Small (Weinheim an Der Bergstrasse, Germany)},
volume = {4},
number = {8},
pages = {1130--1132},
keywords = {Animals, Biological Transport, carbon, Electron, Female, Glomerular Filtration Rate, I2CT, Inbred BALB C, Kidney Glomerulus, Mice, Microscopy, Nanoparticles, nanotechnology, Nanotubes, Team-Bianco, Transmission},
pubstate = {published},
tppubtype = {article}
}